Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 17.94%2.96M | 42.87%2.22M | -59.32%2.56M | -25.73%19.5M | 18.34%9.16M | -55.87%2.51M | -73.67%1.56M | -9.31%6.28M | -2.30%26.26M | 5.93%7.74M |
| Cost of revenue | 129.62%3.42M | 23.30%3.33M | -53.89%3.24M | -34.58%20.48M | -17.00%7.73M | -75.02%1.49M | -69.60%2.7M | -0.38%7.02M | 6.25%31.31M | -17.18%9.32M |
| Gross profit | -145.24%-461K | 3.32%-1.11M | 7.94%-684K | 80.58%-980.74K | 190.30%1.43M | 466.55%1.02M | 61.52%-1.14M | -494.40%-743K | -94.90%-5.05M | 59.98%-1.58M |
| Operating expense | -19.21%1.31M | -18.14%388K | -45.88%322K | -50.80%2.55M | -27.10%1.56M | -19.13%1.62M | -19.25%474K | 27.41%595K | 165.86%5.17M | 179.86%2.13M |
| Staff costs | -12.18%988K | ---- | ---- | -76.20%674.35K | -34.08%1.09M | -12.18%1.13M | ---- | ---- | 337.74%2.83M | 163.60%1.65M |
| Selling and administrative expenses | -42.89%229K | -23.29%303K | -54.53%236K | -16.48%1.69M | -8.94%377K | -41.72%401K | -25.19%395K | 31.06%519K | 177.44%2.03M | 177.15%414K |
| -Selling and marketing expense | ---- | ---- | ---- | -55.25%44.84K | ---- | ---- | ---- | ---- | 577.69%100.2K | ---- |
| -General and administrative expense | -42.89%229K | -23.29%303K | -54.53%236K | -14.47%1.65M | -8.94%377K | -41.72%401K | -25.19%395K | 31.06%519K | 169.17%1.93M | 175.08%414K |
| Other operating expenses | -2.15%91K | 7.59%85K | 13.16%86K | 18.75%412.02K | 30.00%91K | 181.82%93K | 33.90%79K | 7.04%76K | -39.01%346.97K | -84.75%70K |
| Total other operating income | ---- | ---- | ---- | 618.55%233.3K | ---- | ---- | ---- | ---- | 7,630.48%32.47K | ---- |
| Operating profit | -194.83%-1.77M | 7.66%-1.49M | 24.81%-1.01M | 65.51%-3.53M | 96.50%-130K | 73.68%-600K | 54.55%-1.62M | -126.01%-1.34M | -125.33%-10.23M | -191.78%-3.71M |
| Net non-operating interest income (expenses) | 12.78%-614K | -0.31%-657K | 0.46%-652K | -7.37%-2.68M | 3.06%-665K | -7.65%-704K | -8.26%-655K | -20.18%-655K | -165.49%-2.49M | -56.79%-686K |
| Non-operating interest income | 18.18%13K | -33.33%2K | 77.78%16K | 616.13%63.28K | 3,500.00%36K | -26.67%11K | --3K | --9K | -96.85%8.84K | -98.02%1K |
| Non-operating interest expense | -12.31%627K | 0.15%659K | 0.60%668K | 9.52%2.74M | 2.04%701K | 6.88%715K | 8.76%658K | 21.83%664K | 105.11%2.5M | 40.74%687K |
| Net investment income | 12K | 16.67%14K | 15K | 52.90%24.15K | 0.00%12K | 300.00%12K | 270.91%15.8K | 420.77%12K | ||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 92.70%-220K | 92.07%-195K | -24.45%-3.22M | -2,857.14%-9.14M | -303.97%-1.08M | -230.96%-3.01M | 22.52%-2.46M | -481.83%-2.59M | 103.04%331.35K | 232.80%529K |
| Income from associates and other participating interests | 0.00%-1K | -1K | 0.00%-1K | -11.96%-2.62K | 0.00%-1K | 0.00%-1K | 0 | -1K | 14.02%-2.34K | -38.12%-1K |
| Special income (charges) | 9,288.46%4.88M | 0 | 0 | -11.11%-954.16K | -22.60%-1.04M | -58.40%52K | 0 | 30K | 80.55%-858.76K | 81.11%-845K |
| Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --13.39K | ---- |
| Less:Write off | -9,288.46%-4.88M | --0 | --0 | 2,630.08%954.16K | 2,860.00%1.04M | ---52K | --0 | ---30K | -27.47%34.95K | -27.37%35K |
| Less:Negative goodwill immediately recognized | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- | -81.69%810.42K | --810K |
| Other non-operating income (expenses) | -281.82%-120K | -19.64%45K | 1,150.00%105K | 300.00%164K | -37.35%52K | 143.14%66K | 380.00%56K | -242.86%-10K | -82K | 83K |
| Income before tax | 151.68%2.17M | 50.95%-2.29M | -4.32%-4.76M | -22.97%-16.27M | 38.36%-2.85M | -533.33%-4.2M | 37.76%-4.67M | -906.40%-4.56M | 36.37%-13.23M | 28.70%-4.62M |
| Income tax | 22.81%-44K | 1.72%-57K | 0.00%-57K | -95.29%-229.14K | -338.46%-57K | -35.71%-57K | -93.33%-58K | -83.87%-57K | 66.08%-117.34K | 95.09%-13K |
| Net income | 153.45%2.21M | 51.57%-2.23M | -4.38%-4.7M | -22.32%-16.04M | 39.43%-2.79M | -566.99%-4.14M | 38.29%-4.61M | -966.82%-4.5M | 35.87%-13.11M | 25.87%-4.61M |
| Net income continuous operations | 153.45%2.21M | 51.57%-2.23M | -4.38%-4.7M | -22.32%-16.04M | 39.43%-2.79M | -566.99%-4.14M | 38.29%-4.61M | -966.82%-4.5M | 35.87%-13.11M | 25.87%-4.61M |
| Noncontrolling interests | -551.89%-691K | 32.76%-548K | 61.84%-224K | 35.63%-2.16M | 46.45%-649K | 92.19%-106K | -35.83%-815K | -222.53%-587K | -89.30%-3.35M | -85.38%-1.21M |
| Net income attributable to the company | 171.98%2.91M | 55.62%-1.68M | -14.33%-4.48M | -42.23%-13.88M | 36.92%-2.14M | -647.63%-4.04M | 44.76%-3.79M | -1,531.25%-3.92M | 47.74%-9.76M | 38.95%-3.39M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 171.98%2.91M | 55.62%-1.68M | -14.33%-4.48M | -42.23%-13.88M | 36.92%-2.14M | -647.63%-4.04M | 44.76%-3.79M | -1,531.25%-3.92M | 47.74%-9.76M | 38.95%-3.39M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 171.77%0.0089 | 56.03%-0.0051 | -13.33%-0.0136 | -40.26%-0.0425 | 38.10%-0.0065 | -639.13%-0.0124 | 45.79%-0.0116 | -1,614.29%-0.012 | 47.94%-0.0303 | 39.31%-0.0105 |
| Diluted earnings per share | 171.77%0.0089 | 56.03%-0.0051 | -13.33%-0.0136 | -40.26%-0.0425 | 38.10%-0.0065 | -639.13%-0.0124 | 45.79%-0.0116 | -1,614.29%-0.012 | 47.94%-0.0303 | 39.31%-0.0105 |
| Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.